Role for GDNF in Biochemical and Behavioral Adaptations to Drugs of Abuse  by Messer, Chad J et al.
Neuron, Vol. 26, 247±257, April, 2000, Copyright ª 2000 by Cell Press
Role for GDNF in Biochemical and Behavioral
Adaptations to Drugs of Abuse
drug exposure has been shown to produce profound
biochemical changes in specific brain regions thought
to mediate the reinforcing or addicting actions of the
Chad J. Messer,* Amelia J. Eisch,*
William A. Carlezon, Jr.,* Kim Whisler,*
Liya Shen,² Daniel H. Wolf,* Heiner Westphal,²
Frank Collins,³ David S. Russell,* drugs (Nestler and Aghajanian, 1997; Pilotte, 1997).
Prominent among these brain regions is the mesolimbicand Eric J. Nestler*§
*Laboratory of Molecular Psychiatry and dopamine system, which encompasses dopaminergic
neurons in the ventral tegmental area (VTA) of the mid-Yale Center for Genes and Behavior
Yale University School of Medicine and brain and their anterior projections to the limbic fore-
brain, for example, the nucleus accumbens (NAc) (KoobConnecticut Mental Health Center
New Haven, Connecticut 06508 et al., 1998; Wise, 1998). Interestingly, chronic exposure
to any of several drugs of abuse, including cocaine,²Laboratory of Mammalian Genes and Development
National Institutes of Health amphetamine, opiates, or alcohol, causes a series of
common biochemical adaptations in the mesolimbic do-Bethesda, Maryland 20892
³Amgen, Inc. pamine system (Nestler et al., 1993). This is not surpris-
ing, since drugs of abuse, despite their very differentThousand Oaks, California 91320
initial mechanisms of action, converge by producing
common functional effects on the VTA-NAc pathway
after acute exposure. In the VTA, chronic drug exposureSummary
increases levels of tyrosine hydroxylase (the rate-lim-
iting enzyme in dopamine synthesis), specific glutamateThe present study examined a role for GDNF in adapta-
tions to drugs of abuse. Infusion of GDNF into the receptor subunits (such as NMDAR1), and glial fibrillary
acidic protein (an intermediate filament protein specificventral tegmental area (VTA), a dopaminergic brain
region important for addiction, blocks certain bio- to glia), and decreases levels of neurofilaments (interme-
diate filament proteins specific to neurons) (Beitner-chemical adaptations to chronic cocaine or morphine
as well as the rewarding effects of cocaine. Con- Johnson and Nestler, 1991; Beitner-Johnson et al., 1992,
1993; Hurd et al., 1992; Sorg et al., 1993; Vrana et al.,versely, responses to cocaine are enhanced in rats by
intra-VTA infusion of an anti-GDNF antibody and in 1993; Ortiz et al., 1995; Fitzgerald et al., 1996). In the
NAc, chronic drug exposure upregulates activity of themice heterozygous for a null mutation in the GDNF
gene. Chronic morphine or cocaine exposure de- cAMP pathway; for example, it increases levels of pro-
tein kinase A (PKA) (Terwilliger et al., 1991) and alsocreases levels of phosphoRet, the protein kinase that
mediates GDNF signaling, in the VTA. Together, these induces stable isoforms of DFosB, a novel Fos-family
transcription factor (Hope et al., 1994; Nye and Nestler,results suggest a feedback loop, whereby drugs of
abuse decrease signaling through endogenous GDNF 1996; Pich et al., 1997). It has been possible to directly
relate several of these biochemical adaptations to thepathways in the VTA, which then increases the behav-
ioral sensitivity to subsequent drug exposure. behavioral plasticity associated with chronic drug ad-
ministration (see Discussion).
Some of the adaptations seen in response to chronicIntroduction
drug exposure (for example, the reduction in neurofila-
ments and induction of glial filaments) are reminiscentNeurotrophic factors are best studied for their role in
of a state of neural insult or injury. Moreover, drug expo-the growth and differentiation of neurons during devel-
sure is reported to cause morphological changes bothopment. More recently, they also have been implicated
in VTA dopamine neurons (Sklair-Tavron et al., 1996)in many forms of plasticity within the adult nervous sys-
and in their target neurons in the NAc (Robinson andtem. For example, electrically and chemically induced
Kolb, 1997, 1999). These observations raise the possibil-seizures (Gall and Isackson, 1989; Zafra et al., 1991;
ity that neurotrophic factors may be involved in someKokaia et al., 1993), as well as antidepressant treatments
way in long-term responses to drug exposure. Indeed,(Nibuya et al., 1995), stress (Smith et al., 1995), and
direct infusion of BDNF or related neurotrophins intoopiate withdrawal (Numan et al., 1998), have been shown
the VTA has been shown to block the ability of morphineto regulate levels of expression of several types of neu-
and of cocaine to produce some of their characteristicrotrophic factors in specific regions of adult brain. Induc-
biochemical and morphological effects in this brain re-tion of one factor, BDNF (brain-derived neurotrophic
gion (Berhow et al., 1995, 1996; Sklair-Tavron et al.,factor), is reported to contribute to hippocampal long-
1996). However, this pharmacological effect of exoge-term potentiation (Griesbeck et al., 1996; Patterson et
nous BDNF must be differentiated from a possible role ofal., 1996) and to changes in dendritic sprouting in hippo-
endogenous neurotrophic factor pathways in mediatingcampus after chronic seizures (Vaidya et al., 1999).
some of the long-term responses of the VTA-NAc toThe ability of drugs of abuse to cause addiction can
drug exposure (Nestler et al., 1996).be viewed as a form of neural plasticity. Indeed, chronic
The major objective of the present study was to as-
sess such a role for one particular neurotrophic factor,§ To whom correspondence should be addressed (e-mail: eric.
nestler@yale.edu). GDNF (glial cell line±derived neurotrophic factor). We
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These data led us to consider a role for endogenous
GDNF systems in mediating some of the adaptive re-
sponses of VTA neurons to chronic administration of
drugs of abuse. We present here several lines of evi-
dence consistent with such a role. Infusion of GDNF into
the rat VTA blocks biochemical and behavioral plasticity
to chronic drug exposure, whereas infusion of an anti-
GDNF antibody into the VTA enhances responsiveness
to drugs of abuse. Behavioral responses to drug expo-
sure are also enhanced in mice heterozygous for a null
mutation in the gene that encodes GDNF. Finally,
chronic drug exposure decreases levels of phosphory-
lated Ret in the rat VTA, which further establishes a
link between endogenous GDNF signaling and drugs of
Figure 1. Western Blots Showing Blockade of Biochemical Effects abuse at the level of the mesolimbic dopamine system.
of Cocaine by Intra-VTA Infusion of GDNF
Animals received the following treatments: Veh-Sal, intra-VTA infu-
sion of vehicle plus daily injections of saline for 7 days; Veh-Coc,
Resultsintra-VTA infusion of vehicle plus daily injections of cocaine (20 mg/
kg i.p.) for 7 days; GDNF-Coc, intra-VTA infusion of GDNF (2.5 mg/
day) plus daily injections of cocaine for 7 days. Extracts of VTA Infusion of GDNF into the VTA: Biochemical Effects
and NAc were then subjected to Western blotting for the indicated As a first step in assessing the relationship between
proteins. TH, tyrosine hydroxylase; PKA-C, PKA catalytic subunit. GDNF and drugs of abuse, we examined the ability of
GDNF, infused directly into the rat VTA, to modify bio-
chemical adaptations to chronic drug exposure. GDNFfocused on GDNF for several reasons. First, GDNF en-
was delivered by osmotic minipump (at a dose of 2.5hances the survival and maintains the differentiated
mg/day) through a midline cannula implanted into theproperties of dopaminergic neurons in cell culture and
VTA, and the ability of chronic cocaine or chronic mor-does so far more potently compared to BDNF and other
phine to produce some of their characteristic biochemi-neurotrophins (Lin et al., 1993). Second, GDNF dramati-
cal changes was assessed by Western blotting. Controlcally enhances the survival of midbrain dopamine neu-
animals received equivalent intra-VTA infusions of vehi-rons in vivo after challenge with dopaminergic neurotox-
cle. The results of these experiments are summarizedins such as 6-hydroxydopamine or MPTP (Beck et al.,
in Figure 1 and Tables 1 and 2. GDNF infusion completely1995; Kearns and Gash, 1995). GDNF also protects ani-
blocked the ability of chronic morphine and chronic co-mals from the behavioral deficits associated with such
caine to increase levels of tyrosine hydroxylase in thelesions. Strikingly, a single injection of GDNF into the
VTA. GDNF infusion also blocked the ability of cocainemidbrain can exert such protective effects for at least
to increase levels of the NMDAR1 glutamate receptorone month (Kearns and Gash, 1995; Winkler et al., 1996).
subunit in this brain region. (We could not assess theThird, signaling proteins for GDNF, GFRa1 and the asso-
effect of GDNF on drug regulation of neurofilament pro-ciated protein tyrosine kinase Ret, are both highly en-
teins and glial fibrillary acidic protein, since surgery itselfriched in midbrain dopamine neurons (Treanor et al.,
alters levels of these proteins as we reported previously1996; Trupp et al., 1996, 1997, 1998). The binding of
[Berhow et al., 1995].) Interestingly, infusion of GDNFGDNF to its receptor complex causes the phosphoryla-
into the VTA also blocked the ability of chronic cocainetion and activation of Ret, which then mediates the phys-
iological effects of the neurotrophic factor. exposure to produce characteristic biochemical changes
Table 1. Effect of Intra-VTA Infusion of GDNF on Chronic Morphine-Induced Increases in Tyrosine Hydroxylase Immunoreactivity
in the VTA
Treatment Vehicle 1 Sham Vehicle 1 Morphine GDNF 1 Morphine
GDNF infusions 100 6 9 (8) 136 6 12 (8)a 94 6 9 (8)b
initiated before morphine
administration
GDNF infusions 100 6 19 (4) 184 6 10 (4)a 101 6 20 (4)b
initiated after morphine
administration
Vehicle 1 Sham, animals received intra-VTA infusions of vehicle plus implantation of sham pellets; Vehicle 1 Morphine, animals received
intra-VTA infusions of vehicle plus implantation of morphine pellets; GDNF 1 Morphine, animals received intra-VTA infusions of GDNF plus
implantation of morphine pellets. In the top-row experiment, intra-VTA infusion of GDNF was initiated 2 days before the start of morphine
treatment and continued concurrently throughout morphine treatment; in the bottom-row experiment, infusion of GDNF was initiated 2 days
after the completion of morphine treatment (see Experimental Procedures). VTA extracts were subjected to Western blotting for tyrosine
hydroxylase. GDNF infusions alone had no effect on tyrosine hydroxylase levels (see Table 2). Data are expressed as mean 6 SEM (N)
percentage of Vehicle 1 Sham group.
a p , 0.05, compared to Vehicle 1 Sham, by Student's t test.
b p , 0.05, compared to Vehicle 1 Morphine, by Student's t test.
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Table 2. Effect of Intra-VTA Infusion of GDNF on Biochemical Adaptations to Chronic Cocaine
Protein Vehicle 1 Saline Vehicle 1 Cocaine GDNF 1 Cocaine GDNF 1 Saline
TH (VTA) 100 6 11 (12) 138 6 7 (12)a 79 6 14 (12)c 97 6 8 (4)
NMDAR1 (VTA) 100 6 8 (8) 143 6 5 (8)b 88 6 11 (8)d 115 6 12 (4)
DFosB (NAc) 100 6 4 (12) 147 6 13 (12)b 110 6 12 (12)c 114 6 21 (7)
PKA-C (NAc) 100 6 19 (7) 140 6 13 (8)a 92 6 10 (8)c 113 6 12 (7)
Vehicle 1 Saline, animals received intra-VTA infusions of vehicle plus daily injections of saline for 7 days; Vehicle 1 Cocaine, animals received
intra-VTA infusions of vehicle plus daily injections of cocaine for 7 days; GDNF 1 Cocaine, animals received intra-VTA infusions of GDNF plus
daily injections of cocaine for 7 days; GDNF 1 Saline, animals received intra-VTA infusions of GDNF plus daily injections of saline for 7 days.
VTA and NAc extracts were subjected to Western blotting for the indicated proteins. Data are expressed as mean 6 SEM (N) percentage of
Vehicle 1 Saline group.
a p , 0.05, b p , 0.005, compared to Vehicle 1 Saline; c p , 0.05, d p , 0.005, compared to Vehicle 1 Cocaine, by Student's t test.
Note that the small deviations from 100% seen in some of the GDNF 1 Saline values are not significant and within experimental error.
in the NAc, including induction of protein kinase A cata- to reverse as well as prevent drug-induced plasticity in
this brain region.lytic subunit and of the DFosB transcription factor (Fig-
ure 1; Table 2). GDNF infusions by themselves did not
significantly alter levels of these various proteins in the
Infusion of GDNF into the VTA: Behavioral EffectsVTA or NAc. In addition, animals infused with GDNF
We next studied the effect of intra-VTA administrationshowed no untoward effects of the neurotrophic factor:
of GDNF on behavioral responses to cocaine. Rats re-their weights were equivalent to those of vehicle-injected
ceived continuous infusions of GDNF (2.5 mg/day) intocontrols, and the animals showed no gross behavioral
the VTA via osmotic minipump as in the biochemicalabnormalities.
experiments and were tested in a place-conditioningThe ability of GDNF to attenuate biochemical adapta-
paradigm, in which animals learn to associate an envi-tions to chronic drug exposure shows regional specific-
ronment paired with drug exposure. Place conditioningity. Infusion of GDNF into the nearby substantia nigra
is, therefore, considered a measure of the rewarding(another dopamergic nucleus that is located just lateral
properties of a drug. Figure 3 shows the effect of GDNFto the VTA) failed to have the effect of the intra-VTA
on place conditioning to cocaine. In both GDNF- andinfusions: cocaine's ability to induce biochemical adap-
vehicle-infused animals, cocaine established place pref-tations in the VTA was unaffected by intranigral infusions
erences in a dose-dependent manner. However, GDNF-of GDNF (data not shown).
infused animals showed reduced preferences at allInduction of tyrosine hydroxylase is one of the most
doses studied, indicating that GDNF reduces an ani-robust findings with chronic drug exposure and was, as
mal's sensitivity to the rewarding activity of cocaine.a result, used to study the dose response to GDNF
action. In this experiment, we administered GDNF via a
single injection into the rat VTA, based on the reported
ability of this route of administration to protect midbrain
dopamine neurons from neurotoxic lesions (Kearns and
Gash, 1995; Winkler et al., 1996). The results are shown
in Figure 2. The lowest dose of GDNF tested, 0.3 mg, had
no detectable effect on the ability of chronic morphine to
induce tyrosine hydroxylase in this brain region. Moder-
ate doses of GDNF, like the continuous infusion of the
neurotrophic factor, antagonized morphine's effect on
tyrosine hydroxylase without influencing basal levels of
the enzyme. Still higher doses (10 mg) decreased levels
of tyrosine hydroxylase in the VTA and prevented any
induction by morphine.
The experiments described above show that concom-
itant exposure to GDNF can prevent the ability of mor-
phine or of cocaine to induce characteristic biochemical
adaptations in the VTA-NAc pathway. It also was of
interest to determine whether infusion of GDNF into the Figure 2. Dose Response of Blockade of Morphine-Induced In-
VTA could reverse biochemical adaptations already in- crease in Tyrosine Hydroxylase Immunoreactivity by Intra-VTA Injec-
tion of GDNFduced by prior drug exposure. As reported in Table 1,
Sham animals received five daily implantations of sham pellets butone week after cessation of chronic morphine treatment,
no intra-VTA injections. All other animals received a single intra-levels of tyrosine hydroxylase remained significantly ele-
VTA injection of GDNF (0±10 mg), followed by five daily implantationsvated in the rat VTA, consistent with the longevity of
of morphine pellets. Extracts of VTA were subjected to Westernthese effects demonstrated previously (Berhow et al.,
blotting for tyrosine hydroxylase. Data are expressed as mean 6
1995). This persistent increase in tyrosine hyroxylase SEM percentage of Sham group (N 5 4±12 in each treatment group).
was not seen in animals that received intra-VTA infu- Asterisk, p , 0.05, compared to Sham; single caret, p , 0.05, double
caret, p , 0.005, compared to vehicle (0 GDNF), by Student's t test.sions of GDNF, which demonstrates the ability of GDNF
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Figure 3. Effect of Intra-VTA Infusion of GDNF on Place Condition-
ing to Cocaine
Animals received intra-VTA infusions of vehicle or GDNF and were
trained for conditioned place preference with various doses of co-
caine (1.25±10 mg/kg). Data are reported as the mean percentage
change in time spent on the drug-paired side 6 SEM, which provides
a measure of place conditioning (see Experimental Procedures) (N 5
8±12 in each treatment group). Neither the GDNF- nor the vehicle-
infused groups had a baseline preference for either side of the
apparatus before conditioning. GDNF-infused animals displayed a
significantly reduced level of place conditioning to cocaine over this
entire dose range (p , 0.05, two-way ANOVA).
Infusion of Anti-GDNF Antibody into the VTA:
Biochemical and Behavioral Effects
The results obtained with intra-VTA infusions of GDNF
showed that exogenous GDNF can modify the biochemi-
cal and behavioral responses to chronic drug exposure. Figure 4. Effect of Intra-VTA Infusion of Anti-GDNF Antibody on
To determine whether endogenous GDNF is normally Biochemical and Behavioral Responses to Cocaine
involved in drug-induced plasticity, we infused an anti- (A) Veh-Sal, animals received intra-VTA infusion of vehicle plus daily
GDNF antibody into the rat VTA via osmotic minipump. injections of saline for 5 days; Veh-Coc, animals received intra-VTA
infusion of vehicle plus daily injections of cocaine (5 mg/kg i.p.) forThis antibody (termed ªactiveº antibody) was raised
5 days; inactive Ab-Coc, animals received intra-VTA infusions of anagainst a moiety of GDNF that is required for binding
anti-GDNF antibody that does not prevent GDNF from binding toto its receptor and has been shown to block the physio-
its receptor (Ab 1531; see Experimental Procedures) plus daily injec-
logical activity of GDNF in vitro (Xu et al., 1998). As a tions of cocaine for 5 days; and active Ab-Coc, animals received
control, we infused a second anti-GDNF antibody intra-VTA infusions of an anti-GDNF antibody (Ab G90) that does
(termed ªinactiveº antibody), which was raised against prevent GDNF from binding to its receptor plus daily injections of
cocaine for 5 days. Extracts of VTA were subjected to Westerna moiety of GDNF that is not involved in receptor binding
blotting for tyrosine hydroxylase. Data are expressed as mean 6and does not block the physiological activity of GDNF.
SEM percentage of Veh-Sal group (N 5 8 in each treatment group).The two antibodies, in contrast, are equivalent in their
Double asterisk, p , 0.01, compared to three other treatments, by
ability to recognize GDNF in immunoassays. Vehicle was Student's t test.
infused as a further control. Infusion of active antibody (B) Animals received intra-VTA infusion of vehicle, inactive anti-
increased the sensitivity of the animal to biochemical GDNF antibody, or active anti-GDNF antibody and were trained for
conditioned place preference to a threshold dose of cocaine (2.5effects of systemic drug exposure: chronic administra-
mg/kg). Data are reported as the mean percentage change in timetion of a low dose of cocaine (5 mg/kg), which failed to
spent on the drug-paired side 6 SEM, which provides a measureinduce tyrosine hydroxylase in animals that received
of place conditioning (see Experimental Procedures) (N 5 8 in each
intra-VTA infusion of vehicle, significantly increased lev- treatment group). Neither the vehicle- nor antibody-infused groups
els of the enzyme in the VTA of animals infused with the had a baseline preference for either side of the apparatus before
active antibody (Figure 4A). In contrast, this low dose conditioning. Double asterisk, p , 0.01, compared to vehicle and
inactive antibody, by Student's t test.of cocaine had no effect on tyrosine hydroxylase levels
in animals treated with the inactive antibody. Neither
antibody altered levels of tyrosine hydroxylase in the
VTA in the absence of cocaine exposure (data not Intra-VTA infusion of active antibody enabled a thresh-
old dose of cocaine to establish a significant place pref-shown).
Infusion of the active anti-GDNF antibody similarly erence, whereas animals that received intra-VTA infu-
sions of inactive antibody or of vehicle showed no effectincreased an animal's sensitivity to the behavioral ef-
fects of cocaine in the place-conditioning paradigm. (Figure 4B).
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GDNF Knockout Mice: Behavioral
and Biochemical Effects
As a complementary way to examine the influence of
endogenous GDNF pathways on drug responsiveness,
we studied behavioral responses to cocaine in GDNF
knockout mice. Since homozygote knockouts die shortly
after birth from renal complications (Moore et al., 1996;
Pichel et al., 1996; Sanchez et al., 1996), we used hetero-
zygote knockouts that appear normal and do not show
this lethality. Wild-type littermates were used as con-
trols. The mice were studied first in a place-conditioning
paradigm. As shown in Figure 5A, cocaine established
place preferences in wild-type mice in a dose-depen-
dent manner, with significant preferences seen at a
higher dose of cocaine (10 mg/kg), but not at a lower
dose (5 mg/kg). In contrast, GDNF knockout mice devel-
oped high levels of place conditioning to both doses.
These results indicate greater responsiveness of the
knockouts to the rewarding effects of cocaine.
Mice were studied next in a locomotor activity para-
digm. Wild-type and GDNF knockout mice did not differ
in their locomotor response when first placed in the
locomotor chamber, and they showed equivalent habit-
uation in locomotor activity after repeated exposures to
the chamber (data not shown). As shown in Figure 5B,
wild-type and knockout mice also showed equivalent
locomotor activation in response to the initial injection
of cocaine. However, GDNF knockout mice showed sig-
nificantly greater increases in locomotor activity follow-
ing repeated exposures to cocaine, a phenomenon
termed locomotor sensitization.
GDNF knockout mice also exhibited biochemical dif-
ferences, compared to their wild-type littermates, in the
mesolimbic dopamine system. The knockouts showed
dramatically elevated levels of DFosB in the NAc (289 6
Figure 5. Behavioral Responses to Cocaine in GDNF Knockout Mice
10% of wild type; N 5 8; p , 0.01 by Student's t test),
(A) Heterozygote GDNF knockout mice (1/2) and their wild-type
although levels of tyrosine hydroxylase and of NMDAR1 littermates (1/1) were trained for conditioned place preference to
immunoreactivity in the VTA were equivalent to those cocaine (0±10 mg/kg i.p.). Data are reported as the mean percentage
seen in wild-type mice (data not shown). change in time spent on the drug-paired side, which provides a
measure of place conditioning (see Experimental Procedures) (N 5
8±12 in each treatment group). Neither the wild-type nor the knock-Drug Regulation of the GDNF Signaling Pathway
out mice had a baseline preference for either side of the apparatus
in the Mesolimbic Dopamine System before condtioning. Double asterisk, p , 0.05, compared to wild
To determine whether chronic drug exposure alters the type.
expression of GDNF or its receptor complex, we mea- (B) Locomotor activity of heterozygote GDNF knockout mice (1/2)
and their wild-type littermates (1/1) to four daily cocaine injectionssured levels of GDNF, GFRa1, and Ret mRNA in the
(10 mg/kg i.p.). Data are expressed as mean percentage changemesolimbic dopamine system by in situ hybridization.
from baseline locomotor activity (B) 6 SEM (N 5 8±12 in each treat-Previous work has shown that GDNF is expressed at
ment group). Double asterisk, p , 0.01, compared to wild type, by
moderate levels in NAc and related striatal regions, with Student's t test.
no detectable GDNF mRNA seen in the VTA (Trupp et
al., 1997). Conversely, GFRa1 and Ret are enriched in
the VTA and not detectable in the NAc (Treanor et al., does not provide an adequate measure of whether drug
exposure alters the functional activity of the GDNF path-1996; Trupp et al., 1996, 1997). Analysis of drug-naive
rats confirmed this distribution pattern for these mRNAs way within this neural pathway. To address this question
directly, we developed an assay (described in Experi-(e.g., see Figure 6A for GFRa1). Moreover, it was found
that chronic administration of morphine or of cocaine mental Procedures) to quantitate levels of tyrosine-
phosphorylated Ret in the VTA. It is well-establisheddid not significantly alter levels of mRNA expression of
GDNF in the NAc, or of GFRa1 or Ret in the VTA. Chronic that such phosphorylation of Ret is stimulated upon
GDNF binding to the GFRa1-Ret complex and that thismorphine or cocaine administration also failed to alter
levels of Ret immunoreactivity in the VTA as determined phosphorylation results in activation of Ret, which then
mediates subsequent physiological actions of GDNFby Western blotting (Figure 6B).
However, the lack of drug-induced alterations in (Treanor et al., 1996; Trupp et al., 1996, 1998). As a result,
levels of phosphoRet provide a functional measure ofsteady-state levels of expression of GDNF and its recep-
tor components in the mesolimbic dopamine system signaling via GDNF and related factors. By use of this
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what we know about the role of GDNF in the regulation
of dopaminergic neurotransmission. Thus, research to
date has only shown the pharmacological ability of exog-
enously applied GDNF to protect dopamine neurons in
the adult brain in vivo from neurotoxic injury (see Intro-
duction). The results of the present study implicate en-
dogenous GDNF systems in regulating the function of
adult dopamine neurons, in particular, regulating their
responses to drugs of abuse. Moreover, based on our
findings that chronic drug exposure decreases the
phosphorylation of the GDNF signaling protein Ret in
the VTA, we hypothesize further that some of the long-
term effects of morphine and cocaine on the mesolimbic
dopamine system are achieved via perturbation of en-
dogenous GDNF signaling pathways.
The ability of exogenous GDNF to blunt the biochemi-
cal and behavioral responses to drug exposure is con-
sistent with recent evidence for the role played by cer-
tain of these biochemical responses in animal models
of addiction. Increased expression of DFosB in the NAc
has been shown to increase a mouse's sensitivity to the
rewarding and locomotor-activating effects of cocaine
(Kelz et al., 1999). By blocking this induction of DFosB,
GDNF would be expected to blunt increased behavioral
responsiveness as well. Conversely, the enhanced sen-
sitivity of GDNF knockout mice to cocaine could be
explained by their elevated basal levels of DFosB in the
NAc. A similar case can be made for protein kinase A:
Figure 6. Effect of Chronic Drug Exposure on GDNF Receptor Com- activation of the protein kinase, specifically in the NAc,
ponents in the VTA has been shown to increase locomotor responses to
(A) Autoradiograms showing lack of effect of chronic morphine treat- cocaine and amphetamine (Cunningham and Kelley,
ment on levels of GFRa1 mRNA in the VTA. Levels of GFRa1 mRNA 1993; Miserendino and Nestler, 1995), as well as the
were determined by in situ hybridization in sham-treated and chronic rewarding properties of amphetamine in the conditioned
morphine-treated rats. The figure is representative of six animals
reinforcement paradigm (Kelley and Holahan, 1997).studied in each treatment group.
However, activation of the protein kinase in the NAc also(B) Autoradiograms showing the ability of chronic cocaine (coc) or
has been shown to decrease the rewarding propertieschronic morphine (mor) treatment to decrease levels of tyrosine-
phosphorylated Ret (pRet) in the VTA as determined by Western of cocaine in the drug self-administration paradigm (Self
blotting, with no effect seen on levels of total Ret immunoreactivity. et al., 1998). As a result, it is difficult to conclude defini-
Data are expressed as mean percentage of sham 6 SEM (N 5 6±7). tively what contribution to GDNF's behavioral effects
Asterisk, p , 0.05 by Student's t test. are mediated via blockade of the protein kinase A upreg-
ulation in this brain region. The behavioral conse-
quences of GDNF's ability to block the drug-induced
assay, we found that chronic administration of cocaine biochemical adaptations in the VTA (e.g., induction of
or of morphine caused a robust decrease in levels of tyrosine hydroxylase and NMDAR1) remain unknown,
phosphoRet by 65% and 72%, respectively, in the rat since these adaptations have not yet been related di-
VTA (Figure 6B). In contrast, no effect was seen in the rectly to behavioral plasticity. Nevertheless, the fact that
nearby substantia nigra after chronic cocaine (phos- GDNF blocks behavioral responses to drug exposure
phoRet, 93% 6 23% of sham 6 SEM; total Ret, 96% 6 means that the net effect of the neurotrophic factor must
19% of sham; N 5 6±7) or chronic morphine (data not involve biochemical changes that oppose drug action.
shown). The contrast between the effects of GDNF and BDNF
on actions of drugs of abuse is interesting. Intra-VTA
Discussion infusions of BDNF, like those of GDNF, in rats block
some of the biochemical adaptations to morphine and
The major findings of this study are that exogenous cocaine, for example, induction of tyrosine hydroxylase
GDNF, administered directly into the rat VTA, blunts in the VTA and of protein kinase A in the NAc (Berhow
both biochemical and behavioral adaptations to re- et al., 1995). Yet, a recent study showed that BDNF
peated administration of drugs of abuse. The study also dramatically augments an animal's responses to the lo-
establishes that endogenous GDNF systems are re- comotor and rewarding properties of cocaine (Horger et
quired for normal biochemical and behavioral responses al., 1999). Such augmented behavioral responses would
to drug exposure: infusion of anti-GDNF antibody di- make sense if the biochemical adaptations blocked by
rectly into the VTA increases a rat's sensitivity to drug BDNF are homeostatic; that is, they serve to reduce
effects, and mice that lack one copy of the GDNF gene further drug effects. Presumably, these findings indicate
show a similar increase in drug sensitivity. This is a that the net effect of BDNF, in contrast to that of GDNF,
involves biochemical changes that increase behavioralparticularly important observation because it extends
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responses to drug exposure. Consistent with this inter- The findings that GDNF blocks the drug-induced
pretation is the finding that BDNF knockout mice, in upregulation of tyrosine hydroxylase in the VTA and
contrast to GDNF knockout mice, show reduced be- blocks behavioral responses to drugs of abuse may
havioral plasticity to repeated cocaine administration seem surprising given that GDNF is generally believed
(Horger et al., 1999). The biochemical endpoints exam- to enhance, rather than oppose, the dopaminergic phe-
ined in the present study and in the earlier studies of notype. However, direct measures of the effect of GDNF
BDNF likely represent only a small portion of the adapta- on dopamine levels in the substantia nigra and striatum
tions that chronic drug administration causes in the VTA have yielded mixed results. For example, in lesion stud-
and NAc. Therefore, a major goal of future research is ies GDNF rescues toxin-induced decreases in tyrosine
to further characterize the influence of GDNF and BDNF hydroxylase and tissue dopamine levels and in cell cul-
on the mesolimbic dopamine system, with the objective ture enhances the survival of dopamine neurons (e.g.,
of finding differences in the molecular and cellular ac- see Gash et al., 1996, 1998; Winkler et al., 1996; Hebert
tions of the two neurotrophic factors that explain their and Gerhardt, 1997; Akerud et al., 1999). On the other
opposite behavioral effects. hand, in normal rats GDNF is reported to decrease tyro-
The observations that GDNF produces its effects on sine hydroxylase expression (Lu and Hagg, 1997) and
the mesolimbic dopamine system upon local infusion striatal dopamine content (Gash et al., 1998). Moreover,
into the VTA but not into the nearby substantia nigra no prior information is available for the VTA. Indeed, our
and that the GDNF signaling proteins (GFRa1 and Ret) recent finding that GDNF inhibits tyrosine hydroxylase
are enriched in VTA dopamine neurons (Trupp et al., gene transcription in the VTA (Boundy et al., 1998) shows
1997) are consistent with the possibility that GDNF is quite clearly that GDNF's effects on the VTA are more
acting directly on these neurons. This hypothesis is sup- complex than simply ªincreasing the dopaminergic phe-
ported further by our observation that infusion of anti- notype.º Although speculative, one way to reconcile our
GDNF antibody into the VTA, which does not diffuse findings with GDNF's ability to support the survival of
outside of this brain region (see Experimental Proce- dopamine neurons is that GDNF might promote a pro-
dures), produces effects opposite to that of locally- gram of gene expression that supports homeostatic or
applied GDNF. This hypothesis would then suggest that reparative processes in the neurons at the expense of
the ability of GDNF to modify drug-induced adaptations proteins (like tyrosine hydroxylase) that reflect the neu-
(e.g., induction of DFosB, protein kinase A) in the NAc, rons' highly differentiated state (see Cheah and Geffen,
which itself appears to lack GFRa1 and Ret, occurs 1973; Grafstein, 1975).
indirectly via the neurotrophic factor's actions in the One of the most important aspects of the present
VTA. This is consistent with the evidence that induction study is the evidence for a role of endogenous GDNF
of DFosB in the NAc in response to chronic cocaine systems in drug action. We show that disruption of en-
administration can be blocked by a dopamine receptor dogenous GDNF (via anti-GDNF antibody or a genetic
antagonist (Nye et al., 1995). knockout of GDNF) augments drug responsiveness. We
A major question raised by the present study emerges: also show that while chronic drug exposure does not
what are the mechanisms by which GDNF opposes bio- alter levels of expression of GDNF, GFRa1, or Ret in the
chemical adaptations to chronic morphine or chronic mesolimbic dopamine system, it does cause a dramatic
cocaine exposure? The fact that GDNF exerts these decrease in GDNF signaling as evidenced by a 65%±
effects with two structurally divergent drugs makes it 70% reduction in levels of tyrosine-phosphorylated Ret
highly unlikely that an idiosyncratic chemical interaction in the VTA. Such phosphorylation of Ret is known to
between GDNF and drug is involved. The postreceptor reflect its state of activation and to mediate the physio-
signaling pathways by which GDNF produces its physio- logical effects of GDNF and GFRa1 (Treanor et al., 1996;
logical effects remain poorly understood. It is known Trupp et al., 1996). Taken together, these findings sup-
that GDNF produces its effects through GFRa1 and the
port the scheme that the drug-induced decrease in
protein tyrosine kinase Ret. However, subsequent steps
GDNF signaling in the VTA removes a homeostatic feed-
in this signaling pathway have not been established.
back (or counteracting) mechanism on this neural path-Similarly, the mechanisms by which chronic exposure
way and thereby contributes to sensitized biochemicalto a drug of abuse causes the observed biochemical
and behavioral responses to drugs of abuse. It will bechanges in the VTA (e.g., adaptations in tyrosine hydrox-
interesting in future studies to determine the preciseylase, NMDAR1, and neural and glial filaments) are un-
mechanism by which chronic drug administration de-known. It will be interesting in future studies to identify
creases phosphoRet levels specifically within this brainthe precise molecular steps at which cross-talk between
region.drug-regulated and GDNF-regulated signaling path-
To conclude, the results of the present study establishways converge. The mechanisms of convergence may
a functional interaction between GDNF and drugs ofbe quite complex. For example, chronic morphine and
abuse at the level of the mesolimbic dopamine system.cocaine appear to increase levels of tyrosine hydroxy-
The findings highlight the complex types of mechanismslase immunoreactivity in the VTA via a posttranscrip-
that are likely induced in the brain by chronic exposure totional mechanism (Boundy et al., 1998), whereas GDNF,
a drug of abuse. The involvement of GDNF and perhapsat least at higher doses, appears to decrease tyrosine
other neurotrophic factor systems in drug-induced neu-hydroxylase gene transcription in this brain region (Mes-
ral and behavioral plasticity could be particularly impor-ser et al., 1999). This action of GDNF provides one plausi-
tant for the very long-lived changes in brain functionble mechanism, at the molecular level, by which such
associated with addiction. These results also raise thecross-talk between GDNF and drugs of abuse may
occur. interesting possibility that medications targeted to
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chronic morphine treatment as described above. Two days afterGDNF or to its signaling pathway could be useful as
the last pellet implantation, the animals underwent surgery for initia-novel treatment agents for addictive disorders in humans.
tion of intra-VTA infusions. The animals were used 7 days later.
Experimental Procedures
Western Blotting
Immunolabeling of tyrosine hydroxylase and DFosB (Hiroi et al.,Intra-VTA Surgery
1997), NMDAR-1 (Fitzgerald et al., 1996), and PKA-catalytic subunitMale Sprague±Dawley rats (CAMM, Wayne, NJ), weighing 250±300
(Lane-Ladd et al., 1997) were performed as described elsewhere.g at the start of the experiment, were used in this study. GDNF
Briefly, brains were removed rapidly from decapitated rats and(Amgen) infusion or infusion of an anti-GDNF antibody (see below;
chilled in ice-cold physiological buffer. For rats, VTA and NAc wereAmgen) involved the implantation of osmotic minipumps (Alzet),
obtained from coronal brain slices using either a 15G syringe needlewhich provide a constant infusion rate of 0.5 ml/hr for up to 10 days,
(for all VTA punches and for NAc punches used to analyze PKA) orconnected to a midline intra-VTA cannula (Berhow et al., 1995).
a 12G syringe needle (for all other NAc punches). For mice, VTAGDNF or anti-GDNF antibody was delivered in a vehicle solution
and NAc punches were obtained by use of a 16G and 15G syringeconsisting of 10 mM sodium phosphate (pH 7.4), 0.9% NaCl, and
needle, respectively. Brain samples were homogenized in 1% SDS.1% bovine serum albumin.
Protein determinations were made using the method of Lowry. Be-The GDNF concentration in the minipump was calculated to result
tween 5 mg and 50 mg of protein were loaded onto SDS-polyacryl-in a delivery of 2.5 mg GDNF per day. This dose was chosen for two
amide gels and subjected to electrophoresis.reasons. First, this dose was on the low end of doses of GDNF that
The following antibodies were used: a rabbit anti-FRA (Fos-relatedhave been shown to be effective at preventing the degeneration of
antigen) antibody for DFosB (1:4,000, M. J. Iadarola, National Insti-substantia nigra dopaminergic neurons after a neurotoxic lesion (Lu
tutes of Health, Bethesda, MD); a rabbit anti-tyrosine hydroxylaseand Hagg, 1997). Second, this dose was also near the low end of
antibody (1:10,000, EugeneTech, Allendale, NJ); a rabbit anti-the dose range of other neurotrophic factors that have been shown
NMDAR1 antibody (1:5,000, S. F. Heinemann, La Jolla, CA); a rabbitto be biochemically and behaviorally active when administered into
anti-protein kinase A-Ca antibody (1:1,000, Santa Cruz Biotechnol-the VTA (Berhow et al., 1995, 1996).
ogy, Santa Cruz, CA), which recognizes both the a and b forms ofTwo anti-GDNF antibodies were used in this study: G90 (Amgen),
the catalytic subunit (Lane-Ladd et al., 1997); and a goat anti-Retwhich is known to block GDNF action in vitro, and 1531 (Amgen),
antibody (1 mg/ml, antibody C-20, Santa Cruz Biotechnology). Pro-which does not block anti-GDNF action in vitro (Xu et al., 1998).
teins were detected using horseradish peroxidase±conjugated IgGHowever, the two antibodies are equivalent in terms of their ability
(1:2,000, Vector, Burlingame, CA) followed by chemiluminescenceto detect GDNF in immunoassays. The antibodies were loaded into
(Dupont NEN, Boston, MA). Equal loading and transfer of proteinsminipumps at a concentration sufficient to yield a delivery of 240
was confirmed by the following: (1) all blots were stained with amidong of antibody per day. Immunohistochemical staining of brains
black; (2) levels of several other proteins (e.g., neurofilament pro-after such antibody infusions demonstrated no detectable diffusion
teins, glial fibrillary acidic protein) were not altered by the drug andof the antibodies beyond the injected area (VTA).
GDNF treatments used; and (3) the same blots used to measureThe implantation surgery technique used for this study is de-
proteins that are drug regulated (e.g., tyrosine hydroxylase) werescribed elsewhere (Berhow et al., 1995). Briefly, animals were anes-
also used to measure levels of these other proteins that were notthetized with 50 mg/kg pentobarbital supplemented with atropine
drug regulated. Levels of immunoreactivity were quantified on a(0.25 ml/kg) and implanted with an osmotic pump connector cannula
Macintosh-based image analysis system and were linear over at(28G cannula, 22G connector; Plastic Products Company). The coor-
least a 3-fold range of tissue concentration used. Levels of proteindinates used were for the midline of the VTA (AP 25.3 mm, DV 8.4
in experimental samples were compared with those of controls;mm). In one experiment, cannulae were placed in the substantia
statistical analyses were performed by use of a Student's t test.nigra with the following coordinates: AP 25.3 mm, DV 7.2 mm,
and ML 6 3.0 mm. Osmotic pumps were placed subcutaneously
between the scapulae and connected to the cannula with PE60 Assay for PhosphoRet
tubing (Clay Adams). The tubing was secured at both ends by Loc- Given the lack of availability of phospho-specific anti-Ret antibodies
Tite, and the cannula was sealed in place using dental cement that are suitable for brain extracts, we developed an alternative
mounted to four skull screws. After the cement dried, animals were method to assay levels of tyrosine-phosphorylated Ret. Like many
sutured, treated with antiseptic, and left under observation on a protein tyrosine kinases that function as transmembrane receptors,
heating pad until they revived. Ret expression is relatively low in brain and difficult to measure in
In some experiments, GDNF (0.3±10 mg) was administered directly crude extracts without an initial partial purification step. Since Ret
into the VTA as a single injection via a Hamilton syringe. The GDNF has been shown to undergo N-linked glycosylation (Takahashi et
was administered in a volume of 0.5 ml over 10 min. The injection al., 1991), we used binding to immobilized lectin for this initial purifi-
site was the same as that used for the implantation procedure. cation, as we have done previously for other receptor tyrosine ki-
nases (Wolf et al., 1999). Binding of Ret to several lectins was as-
sessed by incubating VTA extracts with lectin-biotin conjugates andChronic Drug Treatments
Cocaine hydrochloride (National Institute on Drug Abuse) was ad- precipitating the bound proteins with avidin-agarose beads (Lectin
Kit I, Vector Laboratories, Burlingame, CA) and then probing theministered by i.p. injection in saline; control animals received saline
injections. Morphine was administered by subcutaneous implanta- bound and unbound proteins by Western blotting with an anti-Ret
antibody (see above). Wheat germ agglutinin was found to precipi-tion of pellets (containing 75 mg of morphine base; National Institute
on Drug Abuse) to rats under light halothane anesthesia daily for tate a protein recognized by this antibody with an approximate Mr
of 190 kDa and to completely remove the corresponding prominent5 days. Control animals received sham surgery. These treatment
regimens are based on previous studies, where they have been band from the supernatant. This technique was confirmed by quanti-
tatively purifying Ret from SH-SY5Y cells, a cell line known to ex-shown to produce characteristic biochemical adaptations in the
VTA-NAc (Berhow et al., 1995; Fitzgerald et al., 1996). press Ret. Ret-enriched extracts were then subjected to immuno-
precipitation with anti-phosphotyrosine antibody followed byIn all cocaine experiments, animals underwent surgery for implan-
tation of intra-VTA cannula on day 1. Intra-VTA infusions of vehicle immunoblotting for Ret to obtain a final measure of tyrosine-phos-
phorylated Ret in brain samples.or GDNF were initiated at this time. Cocaine injections were initiated
the day after surgery and were given daily for 5±7 days. For biochem- VTA and substantia nigra punch dissections were obtained from
control and morphine-treated rats as described above, except thatical experiments, animals were used either 6 or 16 hr after the last
cocaine injection. In all morphine experiments, unless stated other- the dissection buffer contained 1 mM NaVO4, an inhibitor of protein
tyrosine phosphatases. Frozen punches were sonicated in a bufferwise, animals underwent surgery for initiation of intra-VTA infusions
or injections on day 1. Morphine pellets were implanted daily for 5 containing 1% sodium dodecyl sulfate, 20 mM HEPES (pH 7.4), 100
mM NaCl, 1 mM NaVO4, 50 mM NaF, 10 mM sodium pyrophosphate,days beginning on day 3. The animals were used the day after the
last pellet implantation. In some experiments, animals first received 20 mg/ml leupeptin, 10 mg/ml pepstatin A, 10 mg/ml aprotinin, and
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1 mM phenylmethylsulfonylfluoride. Aliquots of brain samples (con- days. On days 2, 4, and 6, mice received a saline injection and were
confined to one of the side chambers. On days 3, 5, and 7, micetaining 150 mg of protein) were diluted 10-fold with sonication buffer
with 2% Triton X-100 instead of sodium dodecyl sulfate. Forty micro- received an injection of cocaine and confined to the other side of
the chamber.liters of wheat germ agglutinin-sepharose CL4B beads (Sigma) were
added to each sample and incubated for 4 hr at 48C. Resulting On day 8, the animals were allowed to freely explore the entire
apparatus, and the time spent in each side was again recorded.pellets were washed extensively with ice-cold Triton-X 100 buffer.
Glycosylated proteins were then eluted in 250 ml of the Triton-X This procedure has been shown to produce reliable measures of
place conditioning in mice (Hiroi et al., 1997).100 buffer containing 0.3 M N-acetylglucosamine and omitting the
sodium pyrophosphate. Two micrograms of anti-phosphotyrosine Place-conditioning data are reported as the percent change in
time spent on the drug-paired side. This is calculated by comparingantibody (PY20, BD Transduction Laboratories, Lexington, KY) was
added to each eluate, and the mixtures were incubated overnight the amount of time each animal spent in the drug-paired chamber
before and after conditioning.at 48C. The antibody complexes were precipitated using Protein
G-sepharose beads. Pellets were washed extensively with Triton Locomotor activity and sensitization in mice were measured ex-
actly as described (Hiroi et al., 1997). Briefly, mice were tested atX-100 buffer without sodium pyrophosphate and then subjected to
Western blotting with the anti-Ret antibody described above except the same time each day. The locomotor activity chamber was a
plastic cage (28 3 17 3 12 cm) with ten pairs of photocell beams,that ECL-plus (Amersham) was used for chemiluminescent de-
tection. which divided the box into eleven rectangular fields. Horizontal
movement was counted as locomotor activitiy. For the first 3 daysSeveral controls were performed to validate this assay. Ret was
not detectable in supernatants of wheat germ agglutinin±treated (habituation), mice were placed into the chambers immediately after
saline injections and locomotor activity was measured for 10 min.samples, which confirms complete recovery of Ret by this method.
Ret was also not detectable in samples precipitated by wheat germ From days 4±7, mice were given cocaine injections and placed in
the chambers for 10 min. This short time was used because it avoidsagglutinin in the presence of N-acetylglucosamine (which competes
for glycosylated proteins) nor in samples immunoprecipitated with the complications of stereotypy (Hiroi et al., 1997). Baseline activity
for each animal was taken as the average of the second and thirdanti-phosphotyrosine antibody in the presence of p-nitrophenylphos-
phate (a phosphotyrosine analog). No additional Ret could be pre- habituation days. Data are reported as the percent of activity of this
baseline.cipitated with a second anti-phosphotyrosine immunoprecipitation
step, which confirms complete recovery of phosphoRet by this
method. Aliquots of the same brain samples analyzed for phos- GDNF 1/- Mice
phoRet were also assayed for levels of total Ret immunoreactivity. The generation of GDNF knockout mice has been described else-
Finally, intra-VTA infusion of GDNF was found (3 hr postinfusion) to where (Pichel et al., 1996). GDNF2/2 mice die within 1±2 days of birth,
consistently increase levels of phosphoRet within this brain region but GDNF1/2 mice are viable, normal in size, and indistinguishable
compared to vehicle-infused animals (202% 6 10% of vehicle 6 grossly from their wild-type littermates. Therefore, such heterozy-
SEM; N 5 3). gote GDNF knockout mice were used in this study. Mice were bred
on a C57BL/6J background and used at about 12 weeks of age.
Wild-type littermates were used as controls. All studies were carriedIn Situ Hybridization
out on male animals.In situ hybridization was performed exactly as described by Messer
et al. (1999) on rats treated chronically with morphine or cocaine (see
Acknowledgmentsabove). Oligonucleotide probes were used for detection of GDNF,
GFRa1, and Ret according to published protocols (Treanor et al.,
This work was supported by grants from the National Institute on1996; Trupp et al., 1996, 1997). For detection of GDNF, a 50-mer
Drug Abuse and by the Abraham Ribicoff Research Facilities of thewas used: 59-CCT GCA ACA TGC CTG GCC TAC CTT GTC ACT
Connecticut Mental Health Center, State of Connecticut DepartmentTGT TAG CCT TCT ACT TCG AG-39. For detection of GFRa1, a 49-
of Mental Health and Addiction Services.mer was used: 59-CTT AGT GTG CGG TAC TTG GTG CTG CAG CTC
TGT TCC TTC AGG CAC TGA T-39. For detection of Ret, a 50-mer
was used: 59-TTG GGA CAA AGG AAC TGC ACG GGT AAC ATG Received August 9, 1999; revised March 8, 2000.
TGG AAG TGG TAG AAG GTG CC-39.
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